NCT01313039CompletedEarly Phase 1
Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Early Phase 1
- Status
- Completed
- Sponsor
- University of Miami
- Enrollment
- 4
- Locations
- 1
- Primary Endpoint
- Increase of ER Protein Expression in ER-Negative/Low Breast Cancer
Study Overview
Brief Summary
If AZD6244 is able to increase ER expression in ER-negative/low cancers then it may be possible to effectively use hormonal therapy in these patients resulting in improved outcomes. The investigators propose a single-arm Simon two-step study to examine whether treatment with AZD6244 will result in increased ER expression in ER-negative/low primary breast tumors.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Female breast cancer patient > 18 years.
- •Patients must have biopsy-proven clinical Stage Ic-III invasive breast carcinoma with ≤ 10% ER expression by immunohistochemistry (IHC) analysis.
- •Patients must have a pre-treatment baseline core biopsy or incisional biopsy available for additional testing (ER, protein/gene expression analysis).
- •Patients must have sufficient tumor remaining following diagnostic biopsy that requires an additional definitive surgical procedure per the standard of care. Planned procedure may include lumpectomy or mastectomy as clinically indicated.
- •Patients must have an ECOG Performance Status of 0 -
- •Patients must have the ability to understand and willingness to sign an English or a Spanish language written informed consent document.
Exclusion Criteria
- •Male breast cancer patient.
- •Patients who are pregnant or breast-feeding are excluded from the study due to potential harm to the fetus or nursing infant from the study therapy. Patients of reproductive potential must consent to use of contraception or abstinence to be eligible for the study.
- •Patients may not have received prior chemotherapy or hormonal therapy for treatment of the current breast cancer.
- •Patients should not have known or strongly suspected BRCA mutation by history (genetic testing not required).
- •Patients will have pre-study testing, including history and physical exam, complete blood count, and measurement of renal and hepatic function. Patients will be ineligible for the study if significant abnormalities are detected, in accordance with good medical practice.
Arms & Interventions
AZD6244
Experimental
Intervention: AZ6244 (Drug)
Outcomes
Primary Outcomes
Increase of ER Protein Expression in ER-Negative/Low Breast Cancer
Time Frame: 2 years
To evaluate in a clinical neoadjuvant model whether MEK inhibitor AZD6244 can increase ER protein expression in ER-negative/low breast cancer, as measured by the "ER response rate" by both standard immunohistochemistry and Allred Score.
Secondary Outcomes
- Changes in ER-regulated Gene Expression in E-negative/Low Breast Cancer(2 Years)
- Rate of ER Promoter Methylation in ER-negative/Low Breast Cancer(2 years)
- In Vitro Tamoxifen Response in Tumors(2 years)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
AZD6244 With Cetuximab for Solid Tumors and Colorectal CancerColonic NeoplasmsCancer of the ColonColon NeoplasmsColonic CancerColon CancerNCT01287130National Cancer Institute (NCI)10
Completed
Phase 2
ZD6474 in Treating Patients With Small Cell Lung CancerLung CancerNCT00066313Genzyme, a Sanofi Company
Completed
Phase 2
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...Non Small Cell Lung CarcinomaNCT01229150National Cancer Institute (NCI)89
Completed
Phase 2
AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine TherapyPancreatic CancerNCT00372944AstraZeneca70
Completed
Phase 1
ZD6474 to Treat Advanced Brain Cancer in PatientsRecurrent High-Grade GliomasProgressive Low-Grade GliomasMalignant GliomasNCT00272350National Cancer Institute (NCI)83